Our Newsletter
June 2026
Home > Newsletters > June 2026
Sophisticated cell engineering, made as routine and accessible as an ordinary biologic. ViroVbots™ are built to make the world's most advanced therapies affordable and scalable for every patient. A child in Fazilka, a farmer in Vidarbha, a teacher in Kerala: every Indian patient deserves the therapy that today exists only for the world's wealthiest.
ViroVbots™ are an AI-engineered, patented class of lentiviral vectors built to modify immune cells safely and selectively inside the living body. Instead of extracting and re-engineering a patient's cells over weeks, they work in vivo — purpose-built for T lymphocytes, with applications from in vivo CAR-T generation to broader immune reprogramming. Each particle is a programmable biological agent: an immune-optimized viral envelope, a cell-targeting moiety, producer-level safeguards, and layered genetic controls. The result is a vector that enters and modifies only its intended target while ignoring the liver, spleen, and other tissues that have historically derailed systemic delivery. Its modular design lets the envelope, targeting ligand, regulatory elements, and payload each be swapped independently — without re-engineering the core vector.
Conventional CAR-T costs ₹3–5 crore per patient. ViroVbots™ aim to deliver the same therapy for under ₹10 lakh — a 30-fold reduction — with GMP-compliant capacity for more than 20,000 patients a year.
Cellogen engineers safety into every layer of ViroVbots™, not as an afterthought but as a design principle. Receptor gating detargets the envelope from native receptors and re-targets it to immune-cell markers, so entry happens only on the right cell. CARTRAP sequesters CAR protein inside producer cells so it can’t decorate the vector surface. CD47 “don’t eat me” signals shield particles from phagocytosis. And a built-in cytokine-signalling domain boosts CAR-T persistence.
USA
FDA Releases Draft Guidance to Speed Gene Therapies On June 2, the FDA issued draft guidance on using priorknowledge (platform data, CMC, nonclinical/clinicalresults) to streamline development and approvals forgene therapies, including genome editing. It aims toreduce redundant testing while keeping safetystandards, accelerating access for rare diseases.
INDIA
SPCTT 2026 Conference Highlights Advances The Society for Pediatric Cellular Therapy and Transplant (SPCTT) conference in Bangalore featured sessions on next-gen CAR-T (AI-powered, bispecific/trispecific), BMT improvements, and access challenges. Pioneer clinicians and researchers discussed India-specific hurdles and opportunities for affordable curative therapies for blood disorders.
To Stay Updated with the latest in Cell & Gene Therapy, Subscribe to Our Newsletter
Subscribe Now >Latest Newsletters
